Stem Cell Clinic

Sysmex : and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy- Aiming for the Research &…

In recent years, the significant potential of regenerative medicine and cell therapy have been established in particular in areas that have traditionally been difficult to address with conventional chemically synthesized low molecular weight drugs1 or biopharmaceuticals,2 such as the restoration of tissues and functions lost as a result of aging, illness, autoimmune diseases, or cancer. In particular, research and development on the therapeutic application of stem cells including hematopoietic stem cells, mesenchymal stem cells, and iPS cells have generated significant attention.

Since its foundation, Sysmex has provided network solutions using IoT (Internet of Things) and automated testing flows to improve the safety of healthcare professionals and for the optimization of operational efficiency in clinical laboratories. In addition, while providing quality control testing for companies which develop regenerative medicine products, Sysmex has conducted research and development related to new pre-transplant compatibility testing examining the patient's immune response against the organ or tissue to be transplanted.

Since its inception, JCR has been engaged in the research, development, manufacturing and sales of pharmaceutical products using regenerative medicine, genetic engineering, and gene therapy technologies to advance therapies in the rare disease field. This is exemplified in the field of regenerative medicine, by the approval of TEMCELL HS Inj.,3 the first allogeneic regenerative medicine in Japan (Non-proprietary name: Human (allogeneic) bone marrow-derived mesenchymal stem cells) in February 2016 for the treatment of acute graft-versus-host disease (acute GVHD),4 a serious complication that develops after hematopoietic stem cell transplantation. In recent years, JCR has further streamlined and integrated its expertise around the establishment of groundbreaking medicines for the advancement of highly innovative medicines that could not be developed without such groundbreaking technologies.

In the joint venture, the two companies aim to realize the social implementation of regenerative medicine and cell therapy by integrating Sysmex's expertise in quality control testing technology and knowledge of workflows efficiency using robotics technology, including IoT, with JCR's expertise in developing, manufacturing and marketing regenerative medicine products. AlliedCel Corporation, which is the corporate name of the joint venture following prior discussions regarding the alliance both companies, was established on October 3, 2022. The joint venture will advance programs of the potential for technology development and commercialization, including the project currently being promoted by both companies using hematopoietic stem cell proliferation technology.

The name AlliedCel stands for the joint venture's aspiration to integrate knowledge and expertise from a broad set of collaborators and stakeholders including business partners, patients and their families, with the united goal of unleashing the power of cells in supporting patients in their need for life-changing therapies. Through the research and development of regenerative medicine products using diverse cells such as stem cells, AlliedCel aims to provide appropriate treatment options to patients and improve their prognosis.

Profile of the Joint Venture

Capital reserve:

100 million JPY

President: Hiroyuki Sonoda

(Vice President, Research and Corporate Strategy, Executive Director of Research Division, JCR Pharmaceuticals Co., Ltd.)

Executive Vice President, Member of the Managing Board: Kenji Tsujimoto

(Executive Vice President of Technology Strategy Division, Sysmex Corporation)

About Sysmex Corporation

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values - reliability, confidence, and persistence - benefit all our stakeholders, including employees, partners, and patients. Together we soar.

Disclaimer

Sysmex Corporation published this content on 03 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 October 2022 06:13:01 UTC.

Publicnow 2022

Technical analysis trends SYSMEX CORPORATION

Income Statement Evolution

See original here:
Sysmex : and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy- Aiming for the Research &...

The Importance of Growth Factor Quality in Organoid Cultures – The Scientist

Within a decade from their first demonstration, organoids have become a quintessential tool for fundamental and biomedical research, serving as relevant models for studying human development and disease.1 Animal and classical 2D cell culture models dominated biological research during the late twentieth and early twenty-first centuries. While these models offer unique advantages for understanding cellular signaling pathways, drug action mechanisms, and disease pathologies, one system alone cannot address them all. Therefore, researchers use various systems at different stages of basic and translational research. However, assessing information from different models slows down discovery for human clinical applications.2

Further, several biological phenomena that are specific to humans do not occur in animal models. For example, several human brain cell types are not found in the rodent brain. Also, the human brains neurodevelopmental mechanisms are far more complex compared to those in rodent brains. Moreover, human brain cell physiology differs when grown in 2D cell cultures and cannot reliably predict drug responses at preclinical stages. So far, human 3D organoids are the only system poised to overcome these limitations.

Organoids are small, self-organized 3D tissue cultures derived from adult stem cells, pluripotent stem cells, or primary tissues. They offer a huge advantage over 2D cell cultures by replicating in vivo organ complexity and tissue architecture. Analyzing organoid formation and function provides valuable information about human development, tissue formation, and organ function as well as a direct tool for pharmaceutical drug testing.

Organoid culture overview

Sino Biological

Researchers generate organoid cultures using multipotent or pluripotent stem cells in a 3D matrix, such as Matrigel, under self-organization promoting conditions. The composition of the growth medium is critical for the health and success of organoid cultures, and is typically enhanced with essential growth factors, such asepidermal growth factor (EGF),noggin (NOG), R-spondin (RSPO1),human growth factor (HGF), bone morphogenetic proteins (BMP), andfibroblast growth factor (FGF). These growth factors activate critical signaling pathways in the organoids to drive development or differentiation. Each culture type requires a distinct set of growth factors. For example, human colon organoids require EGF, NOG, and RSPO1 factors for differentiation, whereas human liver organoids need EGF, NOG, FGF10, and BMP7 for differentiation.2

Manufacturers produce these growth factors in eukaryotic expression systems to obtain structurally and functionally viable products. However, this process creates impurities, including secreted proteins and growth factors from the expression cells and their culture medium, affecting organoid survival and growth. Moreover, different cell lines create batch-to-batch variability in growth factor activity, influencing accuracy and reproducibility in organoid cultures.2

Sino Biological developed a host of recombinant growth factors necessary for organoid culture, including human EGF, NOG, RSPO1, and HGF among many others. These pure factors show high bioactivity, minimal endotoxin contamination, and batch-to-batch consistency, enabling optimal and consistent organoid growth.2 For example, using gel electrophoresis and high-performance liquid chromatography, the manufacturer determined the human EGF purity to be more than 95 percent. The activity of the recombinant human EGF was demonstrated by a cell proliferation assay using BALB/c 3T3 mouse embryonic fibroblasts, and the ED50 for this effect was typically 0.02-0.2 ng/mL. In addition, the purified growth factors are proven to promote or inhibit key pathways for proper stem cell development at low concentrations.2

Overall, Sino Biologicals purified growth factors effectively supplement organoid cultures, allowing them to be a trustworthy tool for researchers working to understand human development and disease.

References

See original here:
The Importance of Growth Factor Quality in Organoid Cultures - The Scientist

Growth in Cell and Gene Therapy Market – BioPharm International

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Cell and gene therapies (CGTs) offer significant advances in patient care by helping to treat or potentially cure a range of conditions that have been untouched by small molecule and biologic agents. Over the past two decades, more than 20 CGTs have been approved by FDA in the United States and many of these one-time treatments cost between US$375,00 and US$2 million a shot (1). Given the high financial outlay and patient expectations of these life-saving therapies, it is essential that manufacturers provide integrated services across the whole of the supply chain to ensure efficient biomanufacturing processes and seamless logistics to reduce barriers to uptake.

The following looks at the who, what, when, and why of biomanufacturing and logistics in CGTs in the bio/pharmaceutical industry in more detail.

According to market research, the global gene therapy market will reach US$9.0 billion by 2027 due to favorable reimbursement policies and guidelines, product approvals and fast-track designations, growing demand for chimeric antigen receptor (CAR) T cell-based gene therapies, and improvements in RNA, DNA, and oncolytic viral vectors (1).

In 2020, CGT manufacturers attracted approximately US$2.3 billion in investment funding (1). Key players in the CGT market include Amgen, Bristol-Myers Squibb Company, Dendreon, Gilead Sciences, Novartis, Organogenesis, Roche (Spark Therapeutics), Smith Nephew, and Vericel. In recent years, growth in the CGT market has fueled some high-profile mergers and acquisitions including bluebird bio/BioMarin, Celgene/Juno Therapeutics, Gilead Sciences/Kite, Novartis/AveXis and the CDMO CELLforCURE, Roche/Spark Therapeutics, and Smith & Nephew/Osiris Therapeutics.

Many bio/pharma companies are re-considering their commercialization strategies and have re-invested in R&D to standardize vector productions and purification, implement forward engineering techniques in cell therapies, and improve cryopreservation of cellular samples as well as exploring the development of off-the-shelf allogeneic cell solutions (2).

The successful development of CGTs has highlighted major bottlenecks in the manufacturing facilities, and at times, a shortage of raw materials (3). Pharma companies are now taking a close look at their internal capabilities and either investing in their own manufacturing facilities or outsourcing to contract development and manufacturing organizations (CDMOs) or contract manufacturing organizations (CMOs) to expand their manufacturing abilities (4). Recently, several CDMOsSamsung Biologics, Fujifilm Diosynth, Boehringer Ingelheim, and Lonzahave all expanded their biomanufacturing facilities to meet demand (5).

A major challenge for CGT manufacturers is the seamless delivery of advanced therapies. There is no room for error. If manufacturers cannot deliver the CGT therapy to the patient with ease, the efficacy of the product becomes obsolete. Many of these therapies are not off-the-shelf solutions and therefore require timely delivery and must be maintained at precise temperatures to remain viable. Thus, manufacturers must not only conform to regulations, but they must also put in place logistical processes and contingency plans to optimize tracking, packaging, cold storage, and transportation through the products journey. Time is of the essence, and several manufacturers have failed to meet patient demands, which have significant impacts on the applicability of these agents.

Several CAR T-cell therapies have now been approved; however, research indicates that a fifth of cancer patients who are eligible for CAR-T therapies pass away while waiting for a manufacturing slot (6). Initially, the manufacture of many of these autologous products took around a month, but certain agents can now be produced in fewer than two weeks (7). Companies are exploring new ways to reduce vein-to-vein time (collection and reinfusion) through the development of more advanced gene-transfer tools with CARs (such as transposon, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) among others, and the use of centralized organization with standardized apheresis centers (5). Others are exploring the use of the of allogeneic stem cells including Regen Biopharma, Escape Therapeutics, Lonza, Pluristem Therapeutics, and ViaCord (7).

Several gene therapies have also been approved, mainly in the treatment of rare disease (8). Many companies are evaluating novel gene therapy vectors to increase levels of gene expression/protein productions, reduce immunogenicity and improve durability including Astellas Gene Therapies, Bayer, ArrowHead Pharmaceuticals, Bayer, Bluebird Bio, Intellia Therapeutics, Kystal Biotech, MeiraGTx, Regenxbio, Roche, Rocket Pharmaceuticals, Sangamo Therapeutics, Vertex Pharmaceuticals, Verve Therapeutics, and Voyager Therapeutics (8).

While many biopharma companies have established their own in-house CGT good manufacturing practice (GMP) operation capabilities, others are looking to decentralize manufacturing and improve distribution by relying on external contracts with CDMOs and CMOs such as CELLforCURE, CCRM, Cell Therapies Pty Ltd (CTPL), Cellular Therapeutics Ltd (CTL), Eufets GmbH, Gravitas Biomanufacturing, Hitachi Chemical Advances Therapeutic Solutions, Lonza, MasTHerCell, MEDINET Co., Takara Bio, and XuXi PharmaTech (6, 9, 10).

The top 50 gene therapy start-up companies have attracted more than $11.6 billion in funds in recent years, with the top 10 companies generating US$5.3 billion in series A to D funding rounds (10). US-based Sana Biotechnology leads the field garnering US$700 million to develop scalable manufacturing for genetically engineered cells and its pipeline program, which include CAR-T cell-based therapies in oncology and CNS (Central Nervous System) disorders (11). In second place, Editas Medicine attracted $656.6 million to develop CRISPR nuclease gene editing technologies to develop gene therapies for rare disorders (12).

Overall, CGTs have attracted the pharma industrys attention as they provide an alternative route to target diseases that are poorly served by pharmaceutical and/or medical interventions, such as rare and orphan diseases. Private investors continue to pour money into this sector because a single shot has the potential to bring long-lasting clinical benefits to patients (13). In addition, regulators have approved several products and put in place fast track designation to speed up patient access to these life-saving medicines. Furthermore, healthcare providers have established reimbursement policies and manufacturers have negotiated value- and outcome-based contracts to reduce barriers to access to these premium priced products

On the downside, the manufacture of CGTs is labor intensive and expensive with manufacturing accounting for approximately 25% of operating expenses, plus there is still significant variation in the amount of product produced. On the medical side, many patients may not be suitable candidates for CGTs or not produce durable response due to pre-exposure to the viral vector, poor gene expression, and/or the development of immunogenicity due to pre-exposure to viral vectors. Those that can receive these therapies may suffer infusion site reactions, and unique adverse events such as cytokine release syndrome and neurological problems both of which can be fatal if not treated promptly (14).

Despite the considerable advances that have been made in the CGT field to date, there is still much work needed to enhance the durability of responses, increase biomanufacturing efficiencies and consistency and to implement a seamless supply chain that can ensure these agents are accessible, cost-effective, and a sustainable option to those in need.

Cleo Bern Hartley is a pharma consultant, former pharma analyst, and research scientist.

BioPharm International Vol. 35, No. 10 October 2022 Pages: 4951

When referring to this article, please cite it as C.B. Hartley, "Growth in Cell and Gene Therapy Market," BioPharm International 35 (10) 4951 (2022).

Continue reading here:
Growth in Cell and Gene Therapy Market - BioPharm International

Organ on a Chip Market – Focus on Products and Technologies – Distribution by Type of Product, Application Area, Purpose, and Key Geographical Regions…

ReportLinker

INTRODUCTION It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry.

New York, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Organ on a Chip Market - Focus on Products and Technologies - Distribution by Type of Product, Application Area, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035" - https://www.reportlinker.com/p06323408/?utm_source=GNW The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drugs failure to get approved. Animal testing for preclinical evaluation of drugs sometimes fails to identify toxicity signs caused by a drug in humans. Moreover, these studies are quite expensive, time-consuming and are associated with several ethical concerns. In order to reform the drug approval process and use non-animal testing models for preclinical evaluations, the US democrats and republicans introduced the FDA Modernization Act in 2021. The U.S. Environmental Protection Agency (EPA) has also declared the termination of the funds granted for the studies on mammals by 2035. As a result, several stakeholders have opted to modernize their conventional testing methods in order to cope up with the increasing limitations associated with animal models. One such innovative technology, organ-on-chip has the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system. The use of such novel testing models in drug discovery and toxicity testing has been steadily increasing. Up till now, several pharmaceutical manufacturers and research institutions have embraced the use of these in vivo like in vitro models; however, a remarkable rise in the adoption rate of these models has been observed since the FDA changed its laws towards putting an end on the animal testing models. , The novel organ-on-chip models have various advantages over the traditional animal-based models, including fine control over microenvironment, lower cost, lesser time, easy to use and portable. , Given the inherent benefits of organ-on-chip technology, a number of players have launched their proprietary products in order to expedite preclinical studies of novel drug interventions across a wide array of disease indications. There are several organ-on-chip models, including lung-on-chip, liver-on-chip, heart-on-chip, brain-on-chip and multiple organ models, which are being offered by various players. Apart from offering efficient user-friendly organ-on-chip models, some developers also offer customization of these models as per the client requests. It is worth mentioning that various developers have made significant efforts in developing organ-on-chip technologies, paving the way for new innovations, primarily integrating artificial intelligence driven technology for early detection of pharmaceuticals and toxicity risks, along with detection of unknown mutations. Driven by promising benefits over animal testing, increasing R&D activity and financial support from investors, the organ-on-chip market is anticipated to grow at a commendable pace in the mid to long term.

SCOPE OF THE REPORT The Organ-on-Chip Market, 2022-2035: Focus on Products and Technologies - Distribution by Type of Product (Organ(s) based Models and Disease(s) based Models), Application Area (Cancer Research, Drug Discovery and Toxicity Testing, Stem Cell Research and Tissue Engineering and Regenerative Medicine), Purpose (Research and Therapeutic Production), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of organ-on-chip products and technologies, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes: A general introduction of organ-on-chip, including history and development, classification, advantages and limitations and applications and future perspectives of organ-on-chip. A detailed assessment of the current market landscape of organ-on-chips based on a number of relevant parameters, such as type of offering(s) (chip, plate / system, and technology), type of model (organ(s) based and disease(s) based), status of development (commercialized, developed, and under development), type of technology / platform, number of chips in a plate, material used for construction of chip / plate (polymer, glass and silicon), type of polymer (polydimethylsiloxane, cyclic olefin polymer, cyclic olefin copolymer, elastomer, polycarbonate, polypropylene, polystyrene, polyester, tygon, and styrene TEP), compatible tissue / organ, and application area (cancer research, drug discovery and toxicity testing, stem cell research, and tissue engineering and regenerative medicine). In addition, the chapter provides details on the companies engaged in the development of organ-on-chip products and technologies, along with information on their year of establishment, company size and location of headquarters. Elaborate profiles of the key players developing organ-on-chips (which are presently commercialized), which are headquartered in North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), organ-on-chip product portfolio, recent developments, and an informed future outlook. An in-depth analysis of various patents that have been filed / granted for organ-on-chip, till 2022, based on various relevant parameters, such as type of patent, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes an insightful patent valuation analysis. A detailed brand positioning analysis of the key industry players, highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products and technologies offered, product diversity, and number of patents published. A study of the various grants that have been awarded to research institutes engaged in projects related to organ-on-chip, between 2017 and 2022, based on parameters, such as year of award, support period, amount awarded, funding institute center, grant type, emerging focus area, type of recipient organization, key regions, and leading recipient organizations. An analysis of the partnerships that have been established since 2017, covering various types of partnerships, such as research and development agreements, clinical trial agreements, product development and commercialization agreements, technology integration agreements, and product development and manufacturing agreements of the companies focused on developing organ-on-chip products and technologies. An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small companies (with less than 50 employees) and mid-sized companies (with 51-200 employees) that are focused on developing organ-on-chip products and technologies. A case study on scaffold-free 3D cell culture products, including hanging drop plate, 3D petri dish, and ultra-low attachment plate, featuring a list of more than 60 products that are being used for research and pharmaceutical testing, based on a number of relevant parameters, such as status of development (commercialized and developed, not commercialized), type of system (suspension system, attachment resistant and microfluidic system), type of product (ultra-low attachment plate, plate, hanging drop plate, chips and dish) and material used for fabrication (chemical / polymer based, human based and plant based).

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of organ-on-chip market. Based on multiple parameters, such as overall 3D cell culture market, and share of organ-on-chip, we have provided informed estimates of the evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of type of product (organ(s) based models and disease(s) based models), application area (cancer research, drug discovery and toxicity testing, stem cell research and tissue engineering and regenerative medicine), purpose (research and therapeutic production), key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of discussions held with the following individuals (in alphabetical order of company / organization names): Pierre Gaudriault, (Chief Business Development Officer, Cherry Biotech) Matt Dong-Heon Ha (Chief Executive Officer, EDmicBio) Michael Shuler (President, Hesperos) Jelena Vukasinovic (Chief Executive Officer, Lena Biosciences) Maurizio Aiello (Chief Executive Officer, react4life) Michele Zagnoni (Chief Executive Officer, ScreenIn3D)

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases Press releases from company websites Government policy documents Industry analysts views

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED Who are the leading players engaged in the development of organ-on-chip products and technologies? What are the different application areas where organ-on-chip can be used? Primarily in which geographical regions, are the organ-on-chip developers located? How has the intellectual property landscape of organ-on-chip, evolved over the years? Which partnership models are commonly adopted by stakeholders in the organ-on-chip domain? What are the investment trends and who are the key investors actively engaged in the research and development of organ-on-chip systems? How is the current and future opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the organ-on-chip market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a general introduction to organ-on-chip, covering details on the background of organ-on-chips along with their classification. In addition, it also provides information on various advantages and limitations of such products. It also discusses the various application areas and future perspectives of organ-on-chips market.

Chapter 4 provides a detailed analysis of the current market landscape of organ-on-chips based on a number of relevant parameters, such as type of offering(s) (chip, plate / system, and technology), type of model (organ(s) based and disease(s) based), status of development (commercialized, developed, and under development), type of technology / platform, number of chips in a plate, material used for construction (polymer, glass and silicon), type of polymer (polydimethylsiloxane, cyclo olefin polymer, cyclic olefin copolymer, elastomer, polycarbonate, polypropylene, polysterene, polyester, tygon, and styrene TEP), compatible tissue / organ, and application area (cancer research, drug discovery and toxicity testing, stem cell research, and tissue engineering and regenerative medicine). In addition, the chapter provides details on the companies engaged in the development of organ-on-chip products and technologies, along with information on their year of establishment, company size and location of headquarters.

Chapter 5 features elaborate profiles of the key players engaged in development of organ-on-chip (which are presently commercialized), which are headquartered in North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), organ-on-chip product portfolio, recent developments, and an informed future outlook.

Chapter 6 features in-depth analysis of various patents that have been filed / granted for organ-on-chip, till July 2022, highlighting key trends associated with these patents, across type of patents, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes an insightful patent valuation analysis.

Chapter 7 features brand positioning analysis of the key industry players, highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products and technologies offered, product diversity, and number of patents published.

Chapter 8 features study of the various grants that have been awarded to research institutes engaged in projects related to organ-on-chip, between 2017 and 2022, highlighting various important parameters, such as year of grant award, amount awarded, funding institute, support period, type of grant application, purpose of grant, activity code, emerging focus area, study section involved, type of recipient organization, key project leaders, key regions, and leading recipient organizations.

Chapter 9 features analysis of the partnerships that have been established since 2017, covering various parameters such as, research and development, clinical trial agreement, product development and commercialization agreement, technology integration agreement, and product development and manufacturing agreement of the companies focused on developing organ-on-chip products and technologies.

Chapter 10 features analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (with less than 50 employees) that are focused on developing organ-on-chip products and technologies.

Chapter 11 is a case study featuring scaffold-free 3D cell culture products, including hanging drop plate, 3D petri dish, and ultra-low attachment plate, featuring a list of more than 60 products that are being used for research and pharmaceutical testing, based on a number of relevant parameters, such as status of development (commercialized and developed, not commercialized), type of system (suspension system, attachment resistant and microfluidic system), type of product (ultra-low attachment plate, plate, hanging drop plate, chips and dish) and material used for fabrication (chemical / polymer based, human based and plant based).

Chapter 12 features an insightful market forecast analysis, highlighting the future potential of the market till 2035. The current and future opportunity has further been segmented on the basis of type of product (organ(s) based models and disease(s) based models), application area (cancer research, drug discovery and toxicity testing, stem cell research and tissue engineering and regenerative medicine), purpose (research and therapeutic production), key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). It is worth mentioning that we adopted a top-down approach for this analysis, backing our claims with relevant datapoints and credible inputs from primary research.

Chapter 13 is the summary of the overall report, which presents insights on the contemporary market trends and the likely evolution of the organ-on-chip market.

Chapter 14 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the company and details of the interview held with Pierre Gaudriault (Chief Business Development Officer, Cherry Biotech), Matt Dong-Heon Ha (Chief Executive Officer, EdmicBio), Michael Shuler (President, Hesperos), Jelena Vukasinovic (Chief Executive Officer, Lena Biosciences), Maurizio Aiello (Chief Executive Officer, react4life) and Michele Zagnoni (Chief Executive Officer, ScreenIn3D).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report. Read the full report: https://www.reportlinker.com/p06323408/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Continue reading here:
Organ on a Chip Market - Focus on Products and Technologies - Distribution by Type of Product, Application Area, Purpose, and Key Geographical Regions...